Adverse effects of low dose amiodarone: A meta-analysis

Journal of the American College of Cardiology

Volumn 30, Issue 3, 1997, Pages 791-798

  Vorperian, Vicken R ^a,b   Havighurst, Thomas C ^a,b   Miller, Stephen ^a,b   January, Craig T ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE;

ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; INCIDENCE; LUNG TOXICITY; MAJOR CLINICAL STUDY; META ANALYSIS; NEUROLOGICAL COMPLICATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SKIN TOXICITY; THYROID DISEASE;

EID: 0030930588     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(97)00220-9     Document Type: Review

References (50)

1. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomized trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. Lancet. 344:1994;493-498.
2. Hamer AWF, Arkles LB, Johns JA. Beneficial effects of low dose amiodarone in patients with congestive cardiac failure a placebo-controlled trial . J Am Coll Cardiol. 14:1989;1768-1774.
3. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, et al. Effect of amiodarone on mortality after myocardial infarction a double-blind, placebo-controlled, pilot study . J Am Coll Cardiol. 20:1992;1056-1062.
4. Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias Basel Antiarrhythmic Study of Infarct Survival (BASIS) . J Am Coll Cardiol. 16:1990;1711-1718.
5. Cairns JA, Connolly SJ, Gent M, Roberts R. Post-myocardial infarction mortality in patients with ventricular premature depolarization Canadian Myocardial Infarction Amiodarone Trial pilot study . Circulation. 84:1991;550-557.
6. Graboys TB, Podrid PJ, Lown B. Efficacy of amiodarone for refractory supraventricular tachyarrhythmias. Am Heart J. 4:1983;870-876.
7. Horowitz LN, Spielman SR, Greenspan ANI, et al. Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol. 6:1985;1402-1407.
8. Gold RL, Haffajee CI, Charos G, Sloan K, Baker S, Alpert JS. Amiodarone for refractory atrial fibrillation. Am J Cardiol. 57:1986;124-127.
9. Brodsky MA, Allen BJ, Waler CJ, Casey TP, Luckett CR, Henry WL. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol. 60:1987;572-575.
10. Blevins RD, Kerin NZ, Benaderet D, et al. Amiodarone in the management of refractory atrial fibrillation. Arch Intern Med. 147:1987;1401-1404.
11. Gosselink AT, Crijns HJ, van Gelder IC, Hillige H, Weisfeld AC, Lie KI. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA. 267:1992;3289-3293.
12. Chun HS, Sager TP, Stevenson WG, Nademanee K, Middlekauff HR, Singh BN. Long term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol. 76:1995;47-50.
13. Nademanee K, Singh BN, Hendrickson J. Amiodarone in refractory life threatening arrhythmias. Ann Intern Med. 98:1983;577-584.
14. Haffajee CI, Love JC, Alpert JS, Asdourian GK, Sloan KC. Efficacy and safety of long-term amiodarone in treatment of cardiac arrhythmias dosage experience . Am Heart J. 106:1983;935-943.
15. Mason JW. Drug therapy amiodarone . N Engl J Med. 316:1987;455-466.
16. Rosenbaum MB, Chiale PA, Halpern MS, et al. Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol. 38:1976;934-944.
17. Harris L, McKenna WJ, Rowland E, Holt DW, Storey GC, Krikler DM. Side effects of long-term amiodarone therapy. Circulation. 67:1983;45-51.
18. Multicenter controlled observation of low-dose regimen of amiodarone for treatment of severe ventricular arrhythmias. Am J Cardiol. 53:1984;1564-1569.
19. Middlekauff HR, Wiener I, Saxon LA, Stevenson WG. Low-dose amiodarone for atrial fibrillation: time for a prospective study? Ann Intern Med. 116:(12 Pt 1):1992;1017-1020.
20. Kerin NZ, Aragon E, Faitel K, Frumin H, Rubenfire M. Long term efficacy and toxicity of high- and low-dose amiodarone regimens. J Clin Pharmacol. 29:1989;418-423.
21. Podrid JP. Amiodarone re-evaluation of an old drug . Ann Intern Med. 122:1995;689-700.
22. Kerin NZ, Rubenfire M, Blevins RD, et al. Long-term efficacy, safety and survival of patients with potentially lethal ventricular arrhythmias treated with low-dose amiodarone. Clin Cardiol. 11:(Suppl II):1988;31-40.
23. Kowey PR, Friehling TD, Marinchak RA, Sulpizi AM, Stohler JL. Safety and efficacy of amiodarone the low-dose perspective . Chest. 93:1988;54-59.
24. Cleland J, Dargie H, Ford I. Mortality in heart failure clinical variables of prognostic value . Br Heart J. 58:1987;572-582.
25. Neri R, Mestroni L, Salvi A, Pandullo C, Camerini F. Ventricular arrhythmias in dilated cardiomyopathy efficacy of amiodarone . Am Heart J. 113:1987;707-715.
26. Miller S, Havighurst TC, January CT, Vorperian VR. Incidence of adverse effects with low dose amiodarone therapy [abstract]. Pacing Clin Electrophysiol. 19:(4 Pt II):1996;617.
27. Garguichevich JJ, Ramos JL, Gambarte A, et al. Effect of amiodarone therapy in patients with left ventricular dysfunction and asymptomatic complex ventricular arrhythmias Argentine pilot study of sudden death and amiodarone (EPAMSA) . Am Heart J. 130:(3 Pt 1):1995;494-500.
28. Nademanee K, Feld G, Hendrickson J, et al. Mexiletine a double-blind comparison with procainamide in PVC suppression and open-label sequential comparison with amiodarone in life-threatening ventricular arrhythmias . Am Heart J. 110:1985;923-931.
29. Navaro-Lopez F, Cosin J, Marrugat J, Guindo J, Bayes de Luna A. Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction (SSCD). Am J Cardiol. 72:1993;1243-1248.
30. Dubner SJ, Elencwajg BD, Palma S, Mendelzon R, Ramos A, Bertolas CA. Efficacy of flecainide in the management of ventricular arrhythmias comparative study with amiodarone . Am Heart J. 109:(3 Pt 1):1985;523-528.
31. Cleland JG, Dargie H, Findlay IN, Wilson JT. Clinical, hemodynamic and antiarrhythmic effects of long term treatment with amiodarone of patients in heart failure. Br Heart J. 57:1987;436-445.
32. Carrasco HA, Vicuna AV, Molina C, et al. Effect of low oral doses of disopyramide and amiodarone on ventricular and atrial arrhythmias in chagastic patients with advanced myocardial damage. Int J Cardiol. 9:1985;425-438.
33. Hockings BEF, George T, Mahrous F, Taylor RR, Hajar HA. Effectiveness of amiodarone on ventricular arrhythmias during and after acute myocardial infarction. Am J Cardiol. 60:1987;967-990.
34. Meyer BJ, Amann FW. Additional antianginal efficacy of amiodarone in patients with limiting angina pectoris. Am Heart J. 125:1993;996-1001.
35. Mahmarian JJ, Smart FW, Moye LA, et al. Exploring the minimal dose of amiodarone with antiarrhythmic and hemodynamic activity. Am J Cardiol. 74:1994;681-686.
36. Varin J, Pelissier C, Legendre M, et al. Anti-anginal effect of amiodarone versus delayed-action propranolol a double-blind randomized study [in French] . Arch Mal Coeur Vaiss. 83:1990;1467-1473.
37. Yusuf S, Peto R, Lewis J, Collins R, Slight P. Beta blockade during and after myocardial infarction an overview of randomized trials . Prog Cardiovasc Dis. 27:1985;335-371.
38. Greenland S, Salvan A. Bias in the one-step (Peto) method for pooling study results. Stat Med. 9:1990;247-252.
39. Kelsey JL, Thompson WD, Evans AS. Prospective cohort studies II: Further design considerations and analysis . House J. Methods in Observational Epidemiology. 1986;105-127 Oxford University Press, Oxford.
40. Berlin JA, Laird NM, Sacks HS, Chalmers TC. A comparison of statistical methods for combining event rates from clinical trials. Stat Med. 8:1989;141-151.
41. Greenland S. Interpretation and estimation of summary ratios under heterogeneity. Stat Med. 1:1982;217-227.
42. Nicklas JM, McKenna WJ, Stewart RA, et al. Prospective, double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. Am Heart J. 122:1991;1016-1021.
43. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med. 333:1995;77-82.
44. Sacks H, Berrier J, Reitman D, Ancora-Berk V, Chalmers T. Meta analysis of randomized controlled trials. N Engl J Med. 316:1987;450-455.
45. Dusman RE, Stanton MS, Miles WM, et al. Clinical features of amiodarone-induced pulmonary toxicity. Circulation. 82:1990;51-59.
46. Fraire AE, Kalpalatha GK, Greenberg SD, Cartwright J, Chasen MH. Amiodarone pulmonary toxicity a multi disciplinary review of current status . South Med J. 86:1993;67-77.
47. Holt DW, Tucker GT, Jackson PR, Storey GC. Amiodarone pharmacokinetics. Am Heart J. 106:1983;840-847.
48. Hohnloser SH, Klingenheben T, Singh BN. Amiodarone-associated pro-arrhythmic effect a review with special reference to torsades de pointes tachycardia . Ann Intern Med. 121:1994;529-535.
49. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction EMIAT . Lancet. 349:1997;667-674.
50. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations CAMIAT . Lancet. 349:1997;675-682.